“Global Clinical Trial Imaging Market is anticipated to grow on account of growing need of clinical trial imaging in providing highly relevant data to clinical research and support the primary end point of some clinical trials”, says Visiongain report

05 September 2019
Pharma

Visiongain has launched a new pharma report Clinical Trial Imaging Market Report 2019-2029: By Modality (Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, X-Ray, Other Modalities), End Users (Academic and Government Research Institutes, Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Pharmaceutical Companies, Other End Users) and by Region.

Global clinical trial imaging market is anticipated to grow on account of growing need of clinical trial imaging in providing highly relevant data to clinical research and support the primary end point of some clinical trials. The global market is anticipated to grow at a lucrative CAGR of 6.6% and anticipated to reach USD 1,547.63 Million by 2029.

Technological advances bring important changes to the clinical trial imaging information collection, assessment, and submission. Including information accuracy, consistency, adaptability, and compliance, technology-enabled imaging–specifically, picture analysis software–gives countless advantages to clinical trials. For instance, picture analysis software can be introduced to direct and guide a viewer through the assessment of each picture time point. This minimizes deviations from the protocol and guarantees the unique bias of each reader does not creep into the analysis process. Software-guided reading becomes an important part of the design of the trial and the development of the independent review manual of the trial to help ensure that all images are read consistently and uniformly, minimizing intra/inter-reader variability and the potential for image-related queries.

The increase in the amount of drug findings increases the development of clinical trials, the advances in medical imaging techniques and the increasing acceptance of the same throughout the globe are fueling the demand for clinical trials to implement imaging techniques. The increase in the amount of pharmaceutical and biotechnology businesses makes it imperative that manufacturers supply the finest possible drug or medicine to the end-user, as competition strikes businesses. This factor contributes to the increase of clinical trials as pharmaceutical and biotechnology businesses are carrying out a big amount of new drug findings. For the transmission of clinical imaging information in clinical trials, digital imaging and communications in medicine (DICOM) format and image archiving and communication systems are required.

North America holds majority of market share followed by Europe and will continue to dominate in the future as a result of rising prevalence of chronic diseases combined with increasing geriatric population, higher R&D expenditure, rising number of CROs, and increasing number of pharmaceutical and biotechnology companies to boost the growth of clinical trial imaging market. Asia Pacific is anticipated to grow with the highest CAGR over the forecast period owing to surging demand for specialized and quality healthcare facilities to improve patient’s life among other prominent factors.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global clinical trial imaging market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

For instance, recently in January 2019, a merger contract was signed between BioTelemetry, Inc., and Geneva Healthcare. BioTelemetry, Inc., the leading remote and wireless medical technology company. Geneva Healthcare which is a California based company has created a cloud-based platform to monitor all patients of the physicians. By purchasing the company, BioTelemetry, Inc. will be able to use the precious asset for the clinical trial imaging market and reach higher heights.

The comprehensive market report features companies such as Biomedical Systems Corporation, Bioclinica, Inc., Intrinsic Imaging LLC, Biotelemetry, Inc., Icon PLC, Ixico PLC, Navitas life sciences, Medpace, Parexel International Corporation, Cardiovascular Imaging Technologies, LLC, Radiant Sage LLC, VirtualScopics Inc., Resonance Health, and Worldcare Clinical, LLC among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Diagnostic Imaging market set to grow to $32bn by 2024” says Visiongain report

Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.

20 September 2019

Read

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
Do NOT follow this link or you will be banned from the site!